Britain’s GSK said it would invest 130 million pounds ($163 million) to buy a 10% stake in Germany’s CureVac, launching a collaboration to develop up to five mRNA-based vaccines with technology already being used by the biotech company to develop a COVID-19 vaccine. CureVac’s existing COVID-19 mRNA and rabies vaccines research programmes are not included in the deal, the companies said.